

Biological Activity of Analogues of YM022.¹⁾ Novel (3-Amino Substituted Phenyl)urea Derivatives of 1,4-Benzodiazepin-2-one as Gastrin/Cholecystokinin-B Receptor Antagonists

Masato SATOH,^{*,a} Yoshinori OKAMOTO,^a Hiroyuki KOSHIO,^a Mitsuaki OHTA,^a
Akito NISHIDA,^a Shinobu AKUZAWA,^a Keiji MIYATA,^a Toshiyasu MASE,^a and Graeme SEMPLE^b

Neuroscience/Gastrointestinal Research Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.,^a 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan and Ferring Research Institute, Chilworth Research Centre,^b Chilworth, Southampton, SO16 7NP, U.K. Received February 2, 1996; accepted March 9, 1996

A series of (3-substituted phenyl)urea analogues of the potent gastrin/cholecystokinin (CCK)-B receptor antagonist YM022 has been prepared. Structure-activity relationship studies of this series suggested that a number of analogues retained good *in vitro* potency for gastrin/CCK-B receptor. In particular, the (3-amino substituted phenyl)urea derivatives (10—12) were more potent inhibitors of pentagastrin-induced gastric acid secretion in rats than YM022 on intraduodenal (i.d.) administration.

Key words gastrin/CCK-B receptor antagonist; YM022; structure-activity relationship; pentagastrin-induced gastric acid secretion; 1,4-benzodiazepin-2-one

Since the discovery of the nonpeptidal, potent and selective gastrin/cholecystokinin (CCK)-B receptor antagonist L-365,260 (1),²⁾ several urea derivatives of 3-amino-1,4-benzodiazepin-2-ones have been investigated as target molecules in this area.³⁾ We have recently reported that a 1-arylmethyl derivative, YM022 (2), shows superior *in vitro* and *in vivo* potency.^{1,4)} Incorporation of alkylcarbonylmethyl groups at the 1-position of the benzodiazepine ring system has also been shown to result in retention of the gastrin/CCK-B receptor antagonistic activity.⁵⁾ In addition, the 5-(2-pyridyl) analogues demonstrated significantly improved oral activity.⁶⁾

In our further search for analogues of YM022, we have recently prepared a series of (3-substituted phenyl)urea derivatives and evaluated their structure-activity relationships for gastrin/CCK-B receptor antagonistic activity.

Chemistry and Biology

The target compounds (4—13, Table 1) were prepared from (*RS*)- or (*R*)-3-amino-1,3-dihydro-1-(2-methylphenyl)-5-phenyl-2*H*-1,4-benzodiazepin-2-one (3)¹⁾ by reaction with the corresponding isocyanates, followed by further reactions (hydrolysis, deprotection, etc.), if necessary (Chart 1).

In vitro receptor binding assays were used to measure

affinities at the CCK-B⁷⁾ and CCK-A⁸⁾ receptors. *In vivo* efficacy was measured in anesthetized rats by assaying gastric acid secretion⁹⁾ following intravenous (i.v.) or intraduodenal (i.d.) administration of a test compound 1 h after the start of pentagastrin infusion.

Results and Discussion

The structure-activity relationships for the (3-substituted phenyl)urea analogues of YM022 are shown in Table 1. The attachment of a carboxyl group to the 3-position (4) led to improved selectivity as well as retained affinity for the gastrin/CCK-B receptor compared to YM022, although the insertion of a carboxamide (5) or a nitrile (6) group resulted in reduced potency. Incorporation of nitrogen-substituents (8—13) proved to increase the selectivity for the gastrin/CCK-B receptor over the CCK-A receptor, with equipotent binding affinity to YM022, whereas a nitro function was less effective (7).

In our *in vivo* test, all the compounds were potent inhibitors of pentagastrin-induced gastric acid secretion in rats following i.v. administration, except for a cyclic amino analogue (13). The basic (3-amino substituted phenyl)urea analogues (10—12) showed stronger inhibition of acid secretion than YM022 after i.d. administration at a dose of 0.3 μ mol/kg in rats. This result is similar to





Fig. 1

* To whom correspondence should be addressed.

Table 1. Structure-Activity Relationships for (3-Substituted Phenyl)urea Analogues of YM022



Compound	R	C3-stereo	Binding assay: IC ₅₀ (nM)		Inhibition (%) of acid secretion at 0.1 μmol/kg i.v. in SD rats	Inhibition (%) of acid secretion at 0.3 μmol/kg i.d. in SD rats
			CCK-A ^{a)}	CCK-B ^{b)}		
YM022	CH ₃	R	150	0.11	81 (at 0.03 μmol/kg)	16
4	CO ₂ H	RS	3210	0.40	77	10
5	CONH ₂	RS	2680	4.24	73	8
6	CN	RS	1070	4.22	69	10
7	NO ₂	RS	1310	5.59	62	0
8	NHCHO	R	360	0.09	89	18
9	NH(CH ₃)CHO	R	660	0.04	65	NT
10	NH ₂	R	450	0.24	74	50
11	NHCH ₃	R	310	0.04	87	50
12	N(CH ₃) ₂	R	710	0.17	63	66
13	-N	RS	> 10000	0.38	41	9

a) IC₅₀ (nM) of [³H]L-364,718 binding to rat pancreas membranes. b) IC₅₀ (nM) of [¹²⁵I]CCK-8 binding to rat brain membranes. NT: not tested.




Chart 1

that in our preceding report,⁶⁾ in which the 5-(2-pyridyl) analogues showed improved oral activity in dogs, and provides further evidence that the enhanced basicity of these gastrin/CCK-B receptor antagonists increases their i.d. activity by improving bioavailability.

Experimental

Melting points were determined on a Yanaco MP-500D and are uncorrected. ¹H-NMR spectra were recorded on a JEOL JNN-EX-400, or a JEOL JNN-GX-500 spectrometer with tetramethylsilane as an internal standard. Mass spectra (MS) were recorded on a JEOL JMS DX-300 mass spectrometer. Elemental analysis was performed with a Yanaco MT-5. Column chromatography was performed on silica gel (Merck Kieselgel 60, 70–230 mesh).

3-[3-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]ureido]benzoic Acid (4) Et₃N (113 mg, 1.12 mmol) was added to a solution of methyl isophthalate (202 mg, 1.12 mmol) and diphenylphosphoryl azide (DPPA, 339 mg, 1.23 mmol) in toluene (20 ml).

The mixture was stirred at room temperature for 1 h, refluxed for 1.5 h and cooled. A solution of (RS)-3-amino-1,3-dihydro-1-(2-methylphenacyl)-5-phenyl-2H-1,4-benzodiazepin-2-one (3)¹⁾ (142 mg, 0.37 mmol) in toluene (5 ml) was added and the stirring was continued at room temperature for 1 h. The reaction mixture was successively washed with saturated aqueous NaHCO₃, water and brine, dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt = 1:1) to give the methyl ester of the title compound (151 mg, 72%).

1 N NaOH (0.78 ml) was added to a solution of the above ester (145 mg, 0.26 mmol) in MeOH (4 ml), and the mixture was stirred at 50 °C for 6 h. Then 1 N HCl (0.78 ml) and water (10 ml) were added and the resultant precipitate was collected by filtration to give crude **4**. The crude **4** was purified by silica gel column chromatography (CHCl₃:MeOH = 93:7) to give **4** (42 mg, 30%) after crystallization from ether: mp 254–257 °C (dec.). ¹H-NMR (DMSO-*d*₆) δ: 2.34 (3H, s, CH₃), 5.39 (3H, m, CH₂COPh and C3-H), 7.26–8.04 (18H, m), 9.26 (1H, s). FAB-MS (Pos.) *m/z*: 547 (M+1)⁺. Anal. Calcd for C₃₂H₂₆N₄O₅·0.4H₂O: C, 69.40; H, 4.88; N, 10.12. Found: C, 69.37; H, 4.85; N, 10.11.

3-[3-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzo-

diazepin-3-yl]ureido]benzamide (5) A solution of isobutyl chloroformate (74 mg, 0.54 mmol) in tetrahydrofuran (THF, 1 ml) was added to a solution of **4** (300 mg, 0.55 mmol) and *N*-methylmorpholine (62 mg, 0.61 mmol) in THF (3 ml). The mixture was stirred at room temperature for 15 min, then concentrated NH_4OH (0.3 ml) was added and the stirring was continued overnight. The resultant precipitate was collected by filtration and crystallized from MeOH to give **5** (86 mg, 29%); mp 271–275 °C (dec.). $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 2.34 (3H, s, CH_3), 5.39 (3H, m, CH_2COPh , C3-H), 7.26–7.88 (20H, m), 9.16 (1H, s). FAB-MS (Pos.) m/z : 546 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{32}\text{H}_{27}\text{N}_5\text{O}_4 \cdot 1.25\text{H}_2\text{O}$: C, 67.65; H, 5.23; N, 12.33. Found: C, 67.85; H, 4.83; N, 12.08.

3-[3-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]ureido]benzonitrile (6) Et_3N (85 mg, 0.84 mmol) was added to a solution of 3-cyanobenzoic acid (124 mg, 0.84 mmol) and DPPA (254 mg, 0.92 mmol) in toluene (15 ml). The mixture was stirred at room temperature for 1 h, refluxed for 1 h and cooled. A solution of (*RS*)-**3**¹¹ (107 mg, 0.28 mmol) in toluene (4 ml) was added and the stirring was continued at room temperature for 1 h. The reaction mixture was successively washed with saturated aqueous NaHCO_3 , water and brine, dried over Na_2SO_4 and evaporated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt=2:1) to give **6** (75 mg, 51%) after crystallization from AcOEt–hexane: mp 238–241 °C (dec.). $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 2.33 (3H, s, CH_3), 5.37 (3H, m, CH_2COPh , C3-H), 7.26–7.93 (18H, m), 9.41 (1H, s). FAB-MS (Pos.) m/z : 528 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{33}\text{H}_{25}\text{N}_5\text{O}_3$: C, 72.85; H, 4.78; N, 13.27. Found: C, 72.94; H, 4.84; N, 13.29.

1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-(3-nitrophenyl)urea (7) 3-Nitrobenzoic acid (167 mg, 1.00 mmol), Et_3N (101 mg, 1.00 mmol), DPPA (275 mg, 1.00 mmol) and (*RS*)-**3**¹¹ (107 mg, 0.28 mmol) were treated in the manner described for **6** to give **7** (100 mg, 65%); mp 222–224 °C. $^1\text{H-NMR}$ (CDCl_3) δ : 2.36 (3H, s, CH_3), 5.15 (1H, d, $J=20$ Hz, one of CH_2COPh), 5.30 (1H, d, $J=20$ Hz, one of CH_2COPh), 5.80 (1H, d, $J=5$ Hz, C3-H), 7.16–7.69 (18H, m), 8.24 (1H, s). FAB-MS (Pos.) m/z : 548 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{33}\text{H}_{25}\text{N}_5\text{O}_5 \cdot 0.5\text{H}_2\text{O}$: C, 66.90; H, 4.71; N, 12.58. Found: C, 66.98; H, 4.65; N, 12.72.

(*R*)-1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-(3-formylaminophenyl)urea (8) 3-Formylaminobenzoic acid (308 mg, 1.86 mmol), Et_3N (189 mg, 1.87 mmol), DPPA (565 mg, 2.05 mmol) and (*R*)-**3**¹¹ (357 mg, 0.93 mmol) were treated in the manner described for **6** to give **8** (239 mg, 47%); mp 155 °C (dec.). $^1\text{H-NMR}$ (CDCl_3) δ : 2.27 (3H, d, $J=20$ Hz, CH_3), 5.04 (1H, br, one of CH_2COPh), 5.29 (1H, br, one of CH_2COPh), 5.80 (1H, br s, C3-H), 6.51 (1H, br), 6.95–8.53 (18H, m). FAB-MS (Pos.) m/z : 546 ($M+1$)⁺. $[\alpha]_D^{20} + 122.7^\circ$ ($c=0.51$, CH_2Cl_2). *Anal.* Calcd for $\text{C}_{32}\text{H}_{27}\text{N}_5\text{O}_4 \cdot 0.4\text{H}_2\text{O}$: C, 69.53; H, 5.07; N, 12.67. Found: C, 69.54; H, 5.11; N, 12.44.

(*R*)-1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-[(*N*-formyl-*N*-methylamino)phenyl]urea (9) 3-(*N*-Formyl-*N*-methylamino)benzoic acid (285 mg, 1.59 mmol), Et_3N (161 mg, 1.59 mmol), DPPA (482 mg, 1.75 mmol) and (*R*)-**3**¹¹ (307 mg, 0.80 mmol) were treated in the manner described for **6** to give **9** (312 mg, 70%); mp 125 °C (dec.). $^1\text{H-NMR}$ (CDCl_3) δ : 2.35 (3H, s, PhCH_3), 3.18 (3H, s, NCH_3), 5.14 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.28 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.72 (1H, d, $J=8$ Hz, C3-H), 6.65 (1H, d, $J=8$ Hz), 7.02–7.62 (17H, m), 8.03 (1H, s), 8.37 (1H, s, NCHO). FAB-MS (Pos.) m/z : 560 ($M+1$)⁺. $[\alpha]_D^{20} + 123.4^\circ$ ($c=0.52$, CH_2Cl_2). *Anal.* Calcd for $\text{C}_{33}\text{H}_{29}\text{N}_5\text{O}_4 \cdot 0.3\text{H}_2\text{O}$: C, 70.15; H, 5.28; N, 12.39. Found: C, 70.15; H, 5.32; N, 12.27.

(*R*)-1-(3-Aminophenyl)-3-[2,3-dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]urea (10) 4*N* HCl (2 ml) was added to a solution of **8** (350 mg, 0.64 mmol) in acetone (5 ml) and the mixture was stirred at room temperature for 6 h. The solvent was evaporated *in vacuo*, and the residue was partitioned between CH_2Cl_2 (10 ml) and saturated aqueous NaHCO_3 (5 ml). The organic phase was dried over MgSO_4 and evaporated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt=1:2) to give **10** (220 mg, 65%) after crystallization from CH_2Cl_2 –ether: mp 165–168 °C. $^1\text{H-NMR}$ (CDCl_3) δ : 2.39 (3H, s, CH_3), 5.09 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.30 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.67 (1H, d, $J=8$ Hz, C3-H), 6.34 (1H, dd, $J=2$, 8 Hz), 6.60 (1H, d, $J=8$ Hz), 6.84–7.60 (17H, m). FAB-MS (Pos.) m/z : 518 ($M+1$)⁺. $[\alpha]_D^{20} + 111.0^\circ$ ($c=0.39$, CHCl_3). *Anal.* Calcd for $\text{C}_{31}\text{H}_{27}\text{N}_5\text{O}_3 \cdot 0.4\text{H}_2\text{O}$: C, 70.95; H, 5.34; N, 13.35. Found: C, 70.94; H, 5.40; N, 13.32.

(*R*)-1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-

benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (11) **9** (187 mg, 0.33 mmol) was treated in the manner described for **10** to give **11** (107 mg, 60%); mp 151–153 °C. $^1\text{H-NMR}$ (CDCl_3) δ : 2.40 (3H, s, PhCH_3), 2.79 (3H, s, NCH_3), 5.10 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.31 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.68 (1H, d, $J=8$ Hz, C3-H), 6.33 (1H, d, $J=8$ Hz), 6.58 (1H, d, $J=8$ Hz), 6.80–7.61 (17H, m). FAB-MS (Pos.) m/z : 532 ($M+1$)⁺. $[\alpha]_D^{20} + 128.5^\circ$ ($c=0.17$, CHCl_3). *Anal.* Calcd for $\text{C}_{32}\text{H}_{29}\text{N}_5\text{O}_3 \cdot 0.3\text{C}_6\text{H}_{14}$: C, 72.82; H, 6.00; N, 12.56. Found: C, 72.61; H, 6.09; N, 12.32.

(*R*)-1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-(3-dimethylaminophenyl)urea (12) 3-Dimethylaminobenzoic acid (165 mg, 1.00 mmol), Et_3N (101 mg, 1.00 mmol), DPPA (275 mg, 1.00 mmol) and (*R*)-**3**¹¹ (107 mg, 0.28 mmol) were treated in the manner described for **6** to give **12** (97 mg, 64%); mp 191–193 °C. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 2.33 (3H, s, PhCH_3), 2.84 (6H, s, $\text{N}(\text{CH}_3)_2$), 5.37 (2H, s, CH_2COPh), 6.32 (1H, d, $J=10$ Hz, C3-H), 6.58–7.85 (18H, m), 8.89 (1H, s). FAB-MS (Pos.) m/z : 546 ($M+1$)⁺. $[\alpha]_D^{20} + 128.0^\circ$ ($c=0.54$, DMF). *Anal.* Calcd for $\text{C}_{33}\text{H}_{31}\text{N}_5\text{O}_3$: C, 72.64; H, 5.73; N, 12.84. Found: C, 72.42; H, 5.77; N, 12.86.

1-[2,3-Dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-[3-(1-pyrrolidinyl)phenyl]urea (13) 3-(1-Pyrrolidinyl)benzoic acid¹⁰ (88 mg, 0.46 mmol), Et_3N (47 mg, 0.46 mmol), DPPA (139 mg, 0.51 mmol) and (*RS*)-**3**¹¹ (176 mg, 0.46 mmol) were treated in the manner described for **6** to give **13** (73 mg, 28%); mp 210 °C (dec.). $^1\text{H-NMR}$ (CDCl_3) δ : 1.96 (4H, m, C3 and C4-H of pyrrolidine), 2.39 (3H, s, CH_3), 3.28 (4H, m, C2 and C5-H of pyrrolidine), 5.10 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.30 (1H, d, $J=18$ Hz, one of CH_2COPh), 5.70 (1H, d, $J=5$ Hz, C3-H), 6.38 (1H, s), 6.55 (1H, d, $J=10$ Hz), 6.79–7.59 (17H, m). FAB-MS (Pos.) m/z : 572 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{35}\text{H}_{33}\text{N}_5\text{O}_3$: C, 73.54; H, 5.82; N, 12.25. Found: C, 73.33; H, 6.11; N, 12.11.

Acknowledgment We would like to thank Messrs. H. Kaniwa and T. Tokunaga for the measurements of $^1\text{H-NMR}$ spectra. We are also indebted to Messrs. M. Shimizu and H. Matsumoto (MS) and Ms. T. Yahagi (elemental analysis).

References and Notes

- Satoh M., Kondoh Y., Okamoto Y., Nishida A., Miyata K., Ohta M., Mase T., Murase K., *Chem. Pharm. Bull.*, **43**, 2159–2167 (1995).
- a) Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M., *J. Med. Chem.*, **32**, 13–16 (1989); b) Lotti V. J., Chang R. S. L., *Eur. J. Pharmacol.*, **162**, 273–280 (1989).
- a) Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Garsky V. M., Gilbert K. F., Leighton J. L., Carson K. L., Mellin E. C., Veber D. F., Chang R. S. L., Lotti V. J., Freedman S. B., Smith A. J., Patel S., Anderson P. S., Freidinger R. M., *J. Med. Chem.*, **36**, 4276–4292 (1993); b) Showell G. A., Bourrain S., Neduevel J. G., Fletcher S. R., Baker R., Watt A. P., Fletcher A. E., Freedman S. B., Kemp J. A., Marshall G. R., Patel S., Smith A. J., Matassa V. G., *ibid.*, **37**, 719–721 (1994); c) Bock M. G., DiPardo R. M., Mellin E. C., Newton R. C., Veber D. F., Freedman S. B., Smith A. J., Patel S., Kemp J. A., Marshall G. R., Fletcher A. E., Chapman K. L., Anderson P. S., Freidinger R. M., *ibid.*, **37**, 722–724 (1994).
- Nishida A., Yuki H., Tsutsumi R., Miyata K., Kamato T., Ito H., Yamano M., Honda K., *Jpn. J. Pharmacol.*, **58**, 137–145 (1992);
- Seiple G., Ryder H., Kendrick D. A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K., *Bioorg. Med. Chem. Lett.*, **6**, 51–54 (1996).
- Seiple G., Ryder H., Kendrick D. A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K., *Bioorg. Med. Chem. Lett.*, **6**, 55–58 (1996).
- Chang R. S. L., Lotti V. J., *Proc. Natl. Acad. Sci. U.S.A.*, **83**, 4923–4926 (1986).
- Chang R. S. L., Lotti V. J., Chen T. B., Kunkel K. A., *Mol. Pharmacol.*, **30**, 212–217 (1986).
- Takeuchi K., Furukawa O., Tanaka H., Okabe S., *Gastroenterology*, **90**, 636–645 (1986).
- Seiple G., Ryder H., Szelke M., Satoh M., Ohta M., Miyata K., Nishida A., Ishii, M., *PCT Int. Appl.*, WO 95/06040 (1995).